Orlando Health Ventures — 2023 Investments
2 investments dated 2023 · listed companies and verified rows first · show all
Arrivo Bio develops novel, disease-modifying medicines targeting the root cause of hard-to-treat diseases for which few effective treatment options exist.
BiotechMedical DevicesMorrisville, US
Karen Adams(Executive Officer)Stephen E. Butts(Executive Officer)
Co-investorsRex Health VenturesSolas BioVentures
Sensydia develops non-invasive wireless cardiac monitoring technology using machine learning to diagnose and manage heart disease.
AI & Machine LearningHardwareHealthtechMedical DevicesLos Angeles, US
Anthony Arnold(CEO)inDr. Aman Mahajan(CMO)inRusty Page(President & COO)inKanav Saraf(Executive Officer)Erick Hawkins(Director)Victroia K. Grace(Director)
Co-investorsColle Capital PartnersFrontier Venture Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.






